1. Introduction {#sec1}
===============

Applied nanotechnology is a revolutionary field with immense potential owing to recent advancements in NP-based drug delivery systems. In general, colloidal NPs are the creates that possess physicochemical features with a size range of 1--1000 nm \[[@B1]\]. The aim of most nanodevices is to prevent the degradation of active molecules to have enhanced bioavailability and to regulate their pharmacokinetic profile. However, most drugs are associated with some limitations such as poor water solubility, improper size and surface area, biodistribution and targeting challenges, and low therapeutic index \[[@B2]\]. To overcome these shortcomings, scientists are always in search for the improved, structurally stable therapeutic NPs that offer several advantages over the free drug. The NPs generally offer enormous surface area, high drug loading capacity, feasibility of functionalization with ligands, controlled drug-release capacity, minimal toxicity, biocompatibility, storage stability, and flexibility in the route of administration. Despite the advantages offered by NPs, the challenges associated should be considered before formulating any therapeutic NPs; some of the challenges are as follows \[[@B3], [@B4]\]:Nontargeted NPs could easily be recognized by mononuclear phagocyte system (MPS) present in blood, liver, spleen, lung, and bone marrow.Surface hydrophobicity of NPs is a key factor for enhanced blood components adsorption onto the NP surface.Prolonged circulation time of NPs is a prerequisite for*in vivo* administration until they reach at the target site.Localization of NPs to the tumor following enhanced permeability and retention (EPR) effect could be hindered by abnormal tumor structure leading to ineffective drug uptake.

Surface modification of the NPs with suitable targeting moieties could overcome these challenges to some extent since targeting agents would efficiently carry the active molecule to its specific site of action rather than undesired localization \[[@B5]\]. This concept triggered the development of several approaches for structural modification of NPs. In this regard, numerous drug delivery systems have been tested to deliver the drug in both*in vitro* and*in vivo*models to assess their targeting efficiency. To conquer this challenge, polymeric biodegradable NPs have gained the most attraction over the past few decades for drug delivery. Among all, PLGA, PEG, polylactic acid (PLA), chitosan, gelatin, and polycaprolactone (PCL) are the widely used polymers \[[@B6]\]. In this review, the main focus has been given mostly for the drug delivery systems with PLGA and PEG due to their wide acceptance as a biodegradable and biocompatible polymer \[[@B7]\]. Depending on the preparation methods, NPs possess different definitive properties and release characteristics for the delivery of therapeutic agent \[[@B8], [@B9]\]. Although structural alterations of these NPs may control the reticuloendothelial system (RES) recognition via stealth mechanism, the efficacy of targeted NPs with definite progression has not been standardized yet.

This review presents an overview of different NP targeting strategies with their pros and cons and recent challenges acknowledged by the researchers to date. Particularly, the review will focus on different targets being targeted by NPs, the possible techniques performed to conjugate NPs with targeting agents, and their biological responses in both*in vitro* and*in vivo*studies. Therefore, a detailed understanding of the structure-activity relationship of targeted NPs could be demonstrated in the field of cancer.

2. NP Targeting Strategies {#sec2}
==========================

Conventional therapies are rapidly eliminated from the body and suffer from widespread distribution into nontargeted organs and tissues \[[@B10]\], whereas targeted therapeutic NPs have gained promising attention through offering a "therapeutic strategy" to tackle the requirements for frequent drug administration, higher dose, and unwanted toxicities related to the conventional therapies \[[@B11]\]. Therefore, an improvised treatment regimen with more patient convenience has become a necessity. Ideally, targeting refers to the specific localization of NPs to a desired site rather than indiscriminate distribution throughout the body. Before being accumulated to the diseased site, these targeted NPs are required to overcome external barriers, en route barriers, and cellular barriers \[[@B12]\]. Effective design of an ideal delivery system is the key foundation to overcome these barriers.

There are two major tumor targeting strategies, passive and active targeting, that have been widely studied as shown in [Figure 1](#fig1){ref-type="fig"} \[[@B13]\]. These two strategies are correlated and work to efficiently deliver the drug particles to the target site. Passive targeting takes advantage of the pathophysiological feature of the diseased tissue, commonly tumor, while active targeting of drug carrier initially utilizes the benefits of passive targeting to accumulate into the tumor region and subsequently bind to the target cells using targeting ligand that leads to receptor mediated internalization of NPs into the cells \[[@B14]\].

2.1. Passive Targeting: Advantages and Challenges {#sec2.1}
-------------------------------------------------

Passive targeting depends on tumor microenvironment, EPR effect, and tumor pH to deliver therapeutic agents from the nanocarriers. It is well known that tumor cells grow and proliferate faster than normal cells. This cellular proliferation is associated with an increased metabolic rate that necessitates more nutrients and oxygen supply. In order to compete for the nutrients, the architecture of normal cells become disrupted as well as displaced by tumor cells \[[@B15]\]. Passive targeting allows NPs to accumulate in the neoplastic tissue through EPR effect. The normal vasculature is impermeable to molecules of size \> 2--4 nm, whereas tumors have leaky vasculature facilitating the retention of NPs in the circulation due to its high density associated outer defective porous vasculature structure. In addition, the poor lymphatic drainage facilitates the stagnation of NPs within the neoplastic environment which is also an extra benefit of EPR effect \[[@B16]\]. Hence, passive targeting takes the advantages of the leaky vasculature as well as tumor microenvironment and helps drugs to expose directly at the tumor tissue bypassing systemic metabolism \[[@B17]\]. Ligand mediated active targeting could also utilize EPR effect to cross the vascular barrier \[[@B18]\]. Thus, EPR effect has become one of the principle considerations for the development of targeted drug delivery system.

However, EPR effect is involved with several challenges since macromolecules or NPs can invade into the tumor tissue only if they can avoid the RES and renal clearance. A drug should remain at least 6 hours in the circulation to get accumulated into the neoplastic tissues via EPR effect \[[@B19]\]. EPR effect was reported unsuccessful to maintain stable circulation of NPs in the bloodstream due to size restrictions of the tumor fenestrations. The development of therapeutic nanocarriers with enhanced retention time is still under practical challenge, particularly in clinical tumors, where the blood vessel morphology is very different than that of mice model used in preclinical studies. This could limit the intratumoral distribution of NPs \[[@B20]\]. In addition, the blunt localization and accessibility of drug carriers into the tumor might not be feasible in case of certain tumors (lung cancer). The high interstitial pressure of solid tumors does not allow homogenous distribution of drugs in the tumor. The advantages of passive targeting serve as a dilemma because EPR effect is unable to promote the uptake of NPs by target cells. In parallel, the ability of an encapsulated drug to reach their pharmacological target should also be considered. Although, passive targeting is promoting drug entry into the tumor tissue, material composition, size, and surface properties are also important determinant factors in this matter. The affinity of the drug to retain into the intratumoral environment should be considered before designing drug delivery systems for passive targeting \[[@B21]\]. Recently, scientists are developing NPs that can adapt the tumor microenvironment to selectively target cancer cells. There are several NP formulations in preclinical and clinical trials that are able to tackle the microenvironment through inhibiting angiogenesis, suppressing tumor growth factors, and enhancing several immune cells (T cell, NK cells, and dendritic cells) \[[@B22]\]. Despite the challenges, realistic clinical settings are necessary to obtain benefit of the applied NP treatment. To date, there are several FDA approved NPs such as Doxil (1995), Feridex (1996), Mylotarg (2000), Zevalin (2002), Abraxane (2005, 2013), Oncospar (2006), and Ontac (2008) that utilize EPR effect to accumulate in solid tumors \[[@B23]\].

### 2.1.1. Current Candidates for Passive Targeting {#sec2.1.1}

*Surface Modification of NPs with PEG*. Enhanced hydrophobicity of NPs was found correlated with steric hindrance which was associated with higher particle-particle aggregation and blood opsonization \[[@B4], [@B24]\]. Poloxamers, poloxamines, and PEG are the polymers that are commonly used to increase hydrophilicity and to provide sterically stable stealth NPs \[[@B25]\]. Among all, PEG is the most widely applied polymer to shield the NPs from opsonization and phagocytosis \[[@B26]\]. PEG has the unique ability to be soluble in both aqueous and organic solvents. Therefore, it can result in activated functional end groups at one or both termini for numerous functionalities. The choice of functional groups depends on the reactivity with the hydroxyl groups of PEG. Modifying one hydroxyl group at one end, heterobifunctional PEG can be used to get linked with different macromolecules, peptides, drugs, liposomes, and so forth. However, heterobifunctional PEGs are limited due to the formation of diol, especially for the high molecular weight of PEGs \[[@B27]\]. Modification of the NPs surface with high molecular weight PEG leads to the stabilization of NPs dispersion, while low molecular weight PEG may result in attraction between the particle surfaces and cause instability in the dispersion \[[@B28]\].

Prolonged residing time of therapeutic NPs during lymphatic circulation is a predominant factor to determine their accumulation amplitude to the tumor site. PEGylation improves the residing time of PLGA NPs due to steric stabilization by avoiding MPS recognition. Consequently, relatively lower accumulation in different organs and higher accumulation in tumor cells is observed \[[@B29], [@B30]\].

PEG is an FDA approved polymer for use in the clinic. The chain length, shape, and density of PEG are also determinant factors to govern the NPs surface hydrophilicity and their uptake mechanism in biological systems \[[@B31]\]. One study showed that PEG-modified wheat germ agglutinin-functionalized NPs with shorter surface PEG length were associated with clathrin-mediated endocytosis, while longer surface PEG length resulted in enhanced transcytosis after 4 hours of incubation \[[@B32]\]. As a general observation, the size of NPs increases with increasing the chain length of PEG considered for the respective NP formulation. However, PEG-copolymer blend shows relatively opposite effect due to the amphiphilic nature of the blend \[[@B29]\]. Low surface coverage of NPs exhibits "mushroom" configuration and high coverage provides "brush" conformation where most PEG chains are extended away from the surface. A balance between these two configurations represents the optimal surface coverage \[[@B26]\]. Although PEG prolongs the NPs circulation in blood, it can hamper the release of cargo or hide the functional groups of NPs at the target site. In order to defeat these barriers, introduction of stimuli-sensitive detachable PEG can be used which might facilitate the release of cargo and able to unveil the targeting ligands or functional groups necessary to yield corresponding responses into the target microenvironment \[[@B33]\].

2.2. Active Targeting: Advantages and Challenges {#sec2.2}
------------------------------------------------

Cellular recognition in molecular level could target the tumor cell actively by ligand-receptor, antigen-antibody interactions, and aptamers. Active targeting of the therapeutic drug can be accomplished by coupling drug or nanocarrier with cell-specific targeting moiety called ligands, with or without using cross-linking agents. These targeting moieties have specific affinity for the cell surface antigens (e.g., receptors) and they can differentiate between normal and tumor cells based on the receptor or antigen expression levels \[[@B34]\]. For example, using Herceptin targeted NPs helped to differentiate human epidermal growth factor receptor 2 (HER2) positive and HER2 negative breast cancer cells. Clearly, the active targeting of HER2 receptors on the overexpressed cells with NPs was confirmed \[[@B35]\].

The term "active targeting" defines a specific ligand-receptor interaction which occurs at the target site after reaching via blood circulation and extravasation. Moreover, efficient ligand-receptor interaction depends on some criteria that include availability of the receptor on the target cells and the exclusive expression of target receptors by the target cells but not in the normal healthy cells. Although surface modification could improve the circulation time, availability of sufficient amount of modified NPs around the target is still a practical challenge \[[@B36]\]. It is essential to realize that only a small fraction of modified NPs can reach the target, while the majority of the intravenously administered NPs are deposited in the liver and spleen with a smaller portion in the kidneys and lungs \[[@B37]\]. The reality of tumor targeting is not yet clinically evident to prove active targeted therapy.

Furthermore, aiming multiple surface markers is necessary to succeed in targeted drug delivery due to the fact that tumors possess a heterogeneous nature \[[@B38]\]. Besides, exploration of internalization mechanisms of targeted conjugates depends on the selection of targeting ligands. For targeted therapeutics, the internalization process should accumulate higher amount of drug in the tumor cells following recycling the receptor back onto the cancer cells \[[@B39], [@B40]\].

Targeting ligands would enhance receptor mediated endocytosis that will minimize the nonspecific interaction of NPs with cell membranes. The targeting efficiency of a ligand depends on its type, nature, method of loading, density, and absence/presence of PEG or spacer molecule on NP surface. It is important to design ligands based on the specificity of the antigen overexpressed on a cancerous cell surface. In addition, such antigen specific ligand tagged on outmost layer of NPs should show high affinity for their cognate receptor \[[@B41]\]. Concomitantly, the tumor heterogeneity and adaptability of cancers are barriers to reach an absolute active targeting. Nowadays, along with hypoxia targeted NP, magnetic, ultrasound, and temperature- and pH-sensitive nanoparticulate systems have been developed to provide additional physical stimuli in supporting active targeting based therapy \[[@B42]\].

In spite of the advantages of the active targeting, this approach faces some limitations as well. Mostly, the targeting ligand might expose the NP carrier system to RES. As a result, higher accumulation of NPs could occur in the unwanted organs over the expected one. Sometimes, PEG coating is employed to minimize the interaction of NPs with RES. However, the outmost ligands could shield the PEG molecules and thus prevent the NPs to circulate in lymphatic system for a long duration. In addition, this can also lead to enhanced accumulation in spleen and liver and ultimately limit the purpose of active targeted therapeutic NPs. Although, active targeting has established a toe-hold in the clinical practice, it requires some more effort to occupy the market with full-fledged successful research \[[@B43]\]. In a recently completed phase III trial, Vyxeos liposomes (combination of Daunorubicin and Cytarabine) have performed very efficiently against myeloid leukemia. Also, marketed product Onivyde (liposomal Irinotecan) has been administered in combination therapy against metastatic adenocarcinoma \[[@B44]\]. Other examples including Docetaxel loaded prostate-specific membrane antigen (PSMA) targeted polymeric NPs (phase II) and HER2 targeted liposomal Doxorubicin (phase II/III) are showing promising outcomes. To obtain clinical benefit, the active targeting with NPs may follow a disease driven approach \[[@B45]\].

### 2.2.1. Available Subcellular Targets for Active Targeting {#sec2.2.1}

There are several targets widely studied to understand the binding capacity of targeted drug delivery system at a subcellular level. The receptors (e.g., folate receptor and peptide receptor) are the main targets that allow specific interaction of a ligand with target on the cell through their uptake via endocytosis. Phospholipid membrane of the cells is the target for the synthetic phospholipid analogs which controls the signal transduction mechanisms. Cell surface proteins or antigens are the ideal targets because of their accessibility due to overexpression in tumor cells compared to normal cells \[[@B46]\]. The plasma membrane is another important target because many therapeutic proteins of interest are localized in this area. For example, human immunodeficiency virus (HIV) can be targeted by a membrane anchor inhibitor; and lipidated membrane anchored peptides can inhibit hepatitis B virus entry. Moreover, both intracellular membrane and compartments are also target for drug-ligand conjugates. Ligands of the cell surface receptor (folate and transferrin) mediate the effective transfer of anticancer drug to the early endosomes to inhibit cell signaling system. Several anticancer therapies could target endosomes that have been internalized through receptor mediated endocytosis. Transferrin-drug conjugate is mainly sorted in early endosomes, within which the ligand is released from the receptor. Antigenic peptides can be conjugated to antigens present on major histocompatibility class 1 complex for delivering the antigen-peptide conjugate to the endoplasmic reticulum. Cytosolic delivery can be performed by conjugating cell penetrating peptides with various formulations. In addition, nucleus and mitochondria can also serve as targets for drug-ligand conjugate \[[@B47]\].

### 2.2.2. Current Candidates for Active Targeting {#sec2.2.2}

The unique features of cancer cells can be exploited in the development of targeted delivery system. For example, cancer cells often overexpress tumor antigens, carbohydrate-like structures, or growth factor receptors (e.g., epidermal growth factor receptor). Based on this concept, different types of ligands can be used as active targeting molecules such as antibody, polysaccharide, aptamer, peptide, transferrin, folate, and other small molecules \[[@B48]\]. Several examples of the targeting ligands bound to NPs and their corresponding targets are enlisted in [Table 1](#tab1){ref-type="table"}. Choice of ligand depends on the cells to be targeted \[[@B49]\].

*Folic Acid*. Folic acid is a popular ligand that targets the folate receptors. Folate receptor is overexpressed in solid tumors such as breast, ovarian, lung, uterine, head, and neck cancers while normal tissues lack such abundance of the receptors. This could be an advantage for target ligands to seek out tumor cells \[[@B50]\]. Folate vitamin is an oxidized form of folate coenzyme having the predominant physiological form as "folic acid." Folic acid has 30 times higher affinity for folate receptor than other folate derivatives. Folate conjugated molecules enter the cell through receptor mediated endocytosis process for targeted intracellular delivery of therapeutic agents. Drug conjugates such as liposomes, solid lipid NPs, polymeric NPs, polymers, and micelles are tailored with folate to subside the RES \[[@B51]\]. An experimental study for retinoblastoma by Das and Sahoo showed that the IC~50~ value for folate decorated Curcumin-Nutlin-3a loaded PLGA NPs was 8.6 times lower than folate unconjugated NPs. This dual drug loading was found to reverse multidrug resistance by downregulating multidrug resistance 1 (MRP-1) and lung resistance related proteins (LRP) \[[@B52]\].

*Transferrin*. Transferrin is a 78 kDa monomeric glycoprotein with the capacity of iron transportation in the body. Overexpression of transferrin receptors on cancer cells makes them an attractive target for its suitable ligand to deliver anticancer drugs into target cells. In particular, the abundance of transferrin receptors in brain glioma resulted in the development of the idea to treat glioblastoma using relative ligand-based therapies. Although transferrin receptor is also expressed in normal cells, overexpression of transferrin occurs in malignant transformations. During this transformation for further proliferation, cancer cells require more iron to synthesize DNA which results in overexpression of transferrin receptors \[[@B53]\].

*Angiogenesis Inhibitors*. Vascular endothelial growth factor receptors (VEGFR), integrin, matrix metalloproteinase receptor, and vascular cell adhesion molecule 1 (VCAM-1) are the targets for impairment of angiogenesis in tumor tissue. Integrin receptor is a good target for cancer treatment. Integrin *α*~*v*~*β*~3~ expression is found on activated endothelial cells, melanoma, and glioblastoma. A number of peptides and peptidomimetics have shown encouraging results for binding to *α*~*v*~*β*~3~ integrins. Thus, targeting the integrin receptors will allow the NPs to be internalized through the receptor based uptake mechanism. Peptide sequences like arginylglycylaspartic acid (RGD) has a high affinity for integrin *α*~*v*~*β*~3~ receptors overexpressed on angiogenic vasculatures. NPs loaded angiogenesis inhibitors have the advantage of overcoming physiological barriers and thereby diffuse the NPs through tumor irrespective of the tumor size. Some specific tumors and tumor endothelial cell receptors recognize and bind through the specific sequence of the peptide. For example, RGD grafted PEG-PLGA NPs has been found to enhance the targeting index as well as antitumor efficacy*in vivo*. The binding occurs between the RGD on NP and integrin overexpressed on malignant tumor cells \[[@B43], [@B54]\].

*Other Peptides*. Peptides have gained special interest in targeted delivery due to their small size, low immunogenicity compared to large proteins, high stability, and ease of conjugation with therapeutic NPs \[[@B55]\]. For example, cyclic-LABL peptide with the terminal functional amino group could be covalently attached to carboxyl terminal of the surfactant pluronic F-127 on the Doxorubicin loaded PLGA NP surface \[[@B56]\]. Other examples are listed in [Table 1](#tab1){ref-type="table"}.

*Carbohydrates*. Another group of receptors is the C-type lectin receptors (CLR) that can recognize sugar molecules. There are several exogenous and endogenous CLRs on antigen presenting cells (APC) such as dendritic cells and macrophages. Haddadi et al. showed that carbohydrate mannan conjugated PLGA NPs enhanced dendritic cell maturation and stimulatory capacity compared to the nonconjugated formulation. These mannan conjugated NPs are targeted to the mannose receptor on the APCs \[[@B57]\].

*Biotin*. In addition to the aforementioned receptors for targeting purposes, biotin receptors are also overexpressed in many types of cancer. Studies have shown that biotin-free NPs result in a low degree of tumor reduction as well as survival in mice when compared with biotin conjugated nanoformulations. This might justify the decoration of PLGA NPs with biotin molecules \[[@B58]\].

*Antibodies*. Antibodies are the most diverse and broadly used targeting ligands that offer the advantages of high degree of specificity for the target tissues. However, antibodies should be linked to the NPs properly as impotent binding to NPs without specificity may impair the activity of antibody \[[@B59]\]. HER2, transferrin, and prostate-specific antigen (PSA) receptors are the most common targets for an antibody. Many monoclonal antibodies (mAb) have already been approved by FDA for targeted cancer treatment. Antibody fragments are also used as because they possess longer circulation time, smaller size, and low immunogenicity as well as the ability to overcome the steric hindrance for binding compared to full antibody. For example, antibody fragments (Fab) of anti-GD2 antibodies are used to target disialoganglioside GD2 of neuroblastoma cells. Application of Fab fragments is associated with increased cytotoxicity and binding ability for the target cancer cells of metastatic tumors. Due to their disadvantages, researchers are encouraged to use other ligands and small molecules \[[@B60]\]. Linking the cysteine residue of the fragmented antibody (Fab) to PEG chain results in increased circulation time of the modified NPs \[[@B61]\]. Both Fab and single chain variable fragment (scFv) lack the fragment crystallizable (Fc) domain that is present in the whole antibody responsible for complement activation. The lack of the Fc domain, in turn, reduces the immunogenicity of antibody fragments \[[@B62]\].

*Polysaccharides*. Targets for polysaccharides are still under exploration and investigation. However, polysaccharides such as chitosan, gelatin, and dextran are extensively used as biodegradable material to be incorporated in NPs \[[@B63]\]. Among these polysaccharides, hyaluronic acid (HA) is the natural polysaccharide that binds with HA receptors of target tumors. HA is a hydrophilic molecule that forms the shell and can be conjugated with the hydrophobic PLGA core. Studies showed that Docetaxel loaded PLGA core having HA in the outer surface contributed to a promising active targeting. HA creates a dynamic cloud of hydrophilic chains on the NP surface that repels plasma proteins. These targeted NPs showed better toxicity against breast cancer cells when compared with the nontargeted formulations \[[@B64]\]. Polysaccharide modification of NPs can help to avoid body\'s recognition mechanism. They contain various functional groups that facilitate self-assembly as well as drug conjugation. Using polysaccharides as core components modifies the polarity of the NP as well as colloidal stability. The use of either natural polysaccharides or their synthesized forms is possible. Polysaccharides can alter the surface charge of NPs, prolong the drug contact time with epithelium, enhance the cellular uptake, and increase bioavailability \[[@B65]\]. Chitosan is another naturally available linear polysaccharide that can easily react with other chemical reagents through its repetitive amine groups \[[@B66]\]. Often dual release of hydrophobic and hydrophilic drug could be performed using dual drug-release platform composed of chitosan film loaded with PLGA NPs \[[@B67]\].

*Aptamers*. Aptamers are single-stranded oligonucleotides having several advantages such as high targeting capacity, low production cost, simple synthesis process, and easy storage. Pegaptanib is an FDA approved aptamer bound with VEGF that blocks the interaction with VEGF receptor \[[@B68]\]. PSMA has also become a good target antigen in targeted drug delivery strategies. PSMA is expressed on some normal tissues, salivary glands, small intestine, and proximal renal tubules and overexpressed in prostate cancer cells (100--1000 times higher compared to normal tissues). PSMA is not a secretory protein like PSA and prostatic acid phosphatase (PAP). Rather, it has its own internalization function that increases when attached to anti-PSMA antibodies. Ligands such as scFv, antibodies, and aptamers have been used to target PSMA. Other prostate cancer antigens such as prostate cancer stem cell (CSC), HER2, and Mucin-1 as well as various receptors are ideal targets for prostate cancer treatment as well, but fewer studies have been performed to develop such targeted delivery systems \[[@B69]\]. Studies showed that Docetaxel loaded PLGA-PEG coblock polymer with terminal amine successfully functionalized with RNA aptamer for PSMA targeting was found more cytotoxic compared to the control group (aptamer free NPs). The hydrophilic PEG presents the carboxylic groups on the NP surface and minimizes the nonspecific uptake by the phagocytic system. However in a study, the tumor reduction capacity was shown to be successful in five mice out of seven along with 100% survival rate whereas nontargeted groups showed full tumor reduction with only 57% survival rate \[[@B70]\].

3. Current Approaches for Targeting NPs {#sec3}
=======================================

There are several widely adopted approaches through which NPs could be intricately modified. The two commonly accepted methods include physical adsorption of hydrophilic polymer/drug onto NPs surface and chemical conjugation of ligand/drug to NPs. However, covalent binding method has been found to rule over the adsorption method since*in vivo*opsonins may compete with the adsorbed molecules onto NP surface. Therefore, better approaches have to be explored to structurally modify the end chains of biodegradable polymer \[[@B71]\]. This can be achieved either by priming the NP surface being introduced with a suitable functional group after preparation or by using the premodified polymeric strands for targeted NP preparation \[[@B72]\]. It is well known that the conjugating drug to the carrier in a binary delivery system rarely achieves specific targeting. However, engineered ternary NP consisting of a biocompatible polymer, drug molecule, and a ligand is essential for efficient targeted drug delivery system \[[@B17]\]. Various methods of tailoring targeting agents to NPs surface will be discussed in the following section.

3.1. Covalent Methods {#sec3.1}
---------------------

### 3.1.1. Antibody-NP Covalent Conjugation {#sec3.1.1}

There are many covalent attachment methods being followed to chemically conjugate monoclonal or polyclonal antibodies with the prepared NPs using cross-linkers ([Figure 2](#fig2){ref-type="fig"}). In conjugation chemistry, utility of a spacer molecule is more than complementary for binding of mAb to the NP. Otherwise, the mAb could be self-polymerized and fail to recognize antibody binding sites on the NP \[[@B59]\]. Spacer group can be homobifunctional and heterobifunctional depending on the reactive groups at the end of the spacer arm. Homobifunctional cross-linkers are those having the same reactive chemical group at both ends, whereas these are different in heterobifunctional cross-linkers. The length of different spacer groups needs to be selected to avoid the occurrence of steric hindrance between drug and mAb \[[@B73]\]. Amino acids such as cysteine or cystamine having sulfhydryl group could be covalently attached to NPs resulting in the formation of thiolated NPs with free thiol groups accessible for antibodies or other drugs. 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC/EDAC), tris-carboxyethyl phosphine hydrochloride (TCEP), and dithio-DL-threitol (DTT) have also been used for the synthesis of thiolated NPs \[[@B74]\]. The following methods have been found more common for chemical conjugation utilizing various cross-linkers or spacer molecules.

*(i) Carbodiimide Chemistry for Conjugation*. Followed by the conjugation method based on carbodiimide chemistry, covalent amide bonds are theorized to form between the carboxylic group of NPs and amine group of the antibody or antibody fragment \[[@B75]\]. In brief, EDC reacts with the carboxylic acid groups of PLGA and activates their carbonyl moieties allowing them to be coupled with the functional amino group of antibody in the reaction mixture. NHS or its water-soluble analog (sulfo-NHS) is often included in EDC coupling protocols to improve the coupling efficiency \[[@B76]\]. This strategy was applied for targeted delivery of Docetaxel to cancer cell using an optimized formulation of anti-HER2 mAb decorated PLGA-PEG NPs where the free amine group of PEG was covalently attached to the carboxylic group of antibody \[[@B77]\]. Cirstoiu-Hapca et al. used a two-step carbodiimide reaction to thiolate the carboxylic groups on the surface of poly(DL-lactic acid) NPs. Then, the thiol groups on the Paclitaxel loaded NPs were linked to m-maleimidobenzoyl-N-hydroxy-sulfosuccinimide ester (sulfo-MBS) activated anti-HER2 mAb \[[@B78]\]. In another study, Pseudomonas exotoxin A loaded PLGA NPs were conjugated to fragmented SM5-1 mAb utilizing the carbodiimide chemistry. These NPs are injected into hepatocellular carcinoma SM5-1 binding protein overexpressing tumor xenograft mice model, resulting in tumor regression \[[@B79]\].

Carbodiimide conjugation is also used to obtain activated PLGA NPs preattached with biotin or PEG before treating with EDC/NHS. Cross-linker biotin binding proteins such as Avidin, Streptavidin, and NeutrAvidin can be attached to the biotinylated PLGA NP. In a comparative study with these three cross-linkers, it was found that NeutrAvidin showed higher specificity to the protein compared to Avidin and Streptavidin. Each cross-linker has four biotin binding sites to attach the biotinylated NPs that could lead to aggregation of NPs. Optimization of reagent\'s amount for biotinylation is the key step to overcome this aggregation issue \[[@B80]\]. Methods devoid of using EDC have also been included in this conjugation strategy due to similar reaction methodology. NHS activated palmitic acid (PA) reacts with positively charged Avidin. Various amount of PA-Avidin was added to PLGA NPs to quantify the surface density of Avidin on NPs. With increase in PA-Avidin amount, NP surface roughness was observed. This was attributed to the vesicle formation by PA that could spread onto the NP surface. The modified NPs showed less drastic morphological change in 21 days while plain NPs showed substantial change in morphology indicating the robustness of palmitoylated surface of NPs \[[@B81]\]. Increasing lipophilicity of the fatty acid linked to Avidin was found to increase the surface incorporation of Avidin to the NP. Maximum Avidin incorporation was found with Avidin-linoleic conjugate (approximately 100%). These NPs showed greater than 80% biotinylated horseradish peroxidase ligand binding to the NPs with the highest number (554 ± 72) of ligands per individual NP \[[@B82]\].

*(ii) Maleimide Chemistry for Conjugation*. The maleimide group reacts with sulfhydryl groups resulting in more selective and precise cross-linking. Combining sulfhydryl reactive groups with amine reactive groups through a maleimide heterobifunctional cross-linker provides better flexibility in antibody-NP conjugation \[[@B83]\]. Thiolated NPs were prepared via carbodiimide chemistry where cystamine could bind covalently with carboxylic group activated NPs. Sulfo-MBS was then used as a bifunctional cross-linker to bind the thiolated NPs and NeutrAvidin, which resulted in structurally modified NPs. The binding of model protein NeutrAvidin to the modified NP surface was higher than that of plain NP. NeutrAvidin-biotin binding ability was confirmed and proved no loss in protein activity during the attachment processes to the NPs \[[@B84]\]. In another study, thiol groups could be covalently introduced on PLA in a comparable way \[[@B85]\]. The NPs were formed via salting-out method containing about 25,000 thiol groups per NP. Covalent attachment of anti-HER2 and anti-CD20 antibody to the NPs through sulfo-MBS was performed and their targeting efficacy against target cancer cell lines was investigated. Optimization of the antibody type and spatial configuration rather than increasing its quantity on NP surface was found essential for internalization in human ovarian carcinoma cell (SKOV-3). Anti-HER2 modified NPs showed specific binding and internalization, whereas anti-CD20 modified NPs remained on the cell surface despite the higher number of anti-CD20 molecules bound to the NP surface \[[@B85]\]. While handling with thiol groups containing amine, it is difficult to introduce sufficient number of thiols since thiol groups are rapidly deteriorated in the solution. Modifications can be executed by introducing thiolating reagents such as N-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP), N-succinimidyl S-acetylthioacetate (SATA), and a reducing agent such as DTT. This is an alternative way to introduce thiol groups on NPs followed by reaction with maleimide containing targeting agents \[[@B86]\].

*(iii) Click Chemistry for Conjugation*. Click chemistry is designated to run in mildly reactive conditions of aqueous solutions with 100% coupling efficiency. This coupling process offers some advantages over other bioconjugation strategies as it does not produce any undesirable side products such as dicyclohexylurea formed in carbodiimide reaction. The most common click reaction occurs between copper catalyzed 1,3 dipolar cycloaddition of azides and terminal alkynes known as CuAAC (copper catalyzed azide-alkyne cycloaddition). The 1,3-triazoles formed in this reaction are biocompatible entities approved by FDA to be used in drug formulation. Herein, the discrete PEG or propargyl-dPEG-NHS can be used as a spacer to react with an amine group of antibody. This azido spacer can be prepared in the presence of activating reagents such as EDC and sulfo-NHS at pH 6 \[[@B87]\]. Then the antibody linked azide group can react with terminal alkyne group containing fluorescent labelled PLGA-polymer blend. In recent studies, copper-free azide-alkyne cycloaddition is often used as it can reduce cytotoxicity*in vivo* \[[@B88]\].

*(iv) Conjugation Using Only Spacer*. In addition to the above conjugation methods, NPs can also be activated using a spacer molecule without any chemical modification which has been a new concept into practice for targeted delivery system. Therefore, manipulating NP preparation technique, the formation of unwanted intermediates during the procedure as formed in carbodiimide-amine and maleimide-thiol reactions can be avoided. Recently, Thamake et al. reported that noncovalent insertion of homobifunctional spacer Bis-sulfosuccinimidyl suberate (BS3) to PLGA NPs during the NP preparation can efficiently facilitate the covalent amide bond between the antibody and NP surface. In this one-step simple covalent attachment process, surface functionalization of NPs was performed by the formation of an amide linkage between the carboxylic group of BS3 and the amine group of the ligand upon hydrolysis of the terminal sulfo-NHS groups. The covalent bond between the antibody and BS3 was found with enhanced NP uptake by the cells \[[@B89]\].

### 3.1.2. Polysaccharide-NP Covalent Conjugation {#sec3.1.2}

Chitosan could also form covalent bond between its amine group and carboxylic group of PLGA. The carboxylic moiety of PLGA NPs could be activated by EDC which reacts with amine group of chitosan. These NPs could achieve relatively constant release of the encapsulated anticancer agent mitoxantrone \[[@B90]\]. In another study, immobilization of thiol groups on the chitosan-NP surface was performed by covalent attachment of 2-iminothiolane to the free amino groups of chitosan. Covalent coupling of chitosan with 2-iminothiolane synthesized thiolated chitosan-4-thiobuthyimidine was observed with enhanced mucoadhesive properties. The resulting chitosan-modified NPs showed prolonged residence time on the small intestinal mucosa compared to chitosan-free PLGA NPs \[[@B91]\]. Similarly, carbodiimide activated carboxylic group of PLGA could be covalently attached to amino group of trimethylchitosan to form an amide bond. This trimethylated chitosan inclusion was found to form hydrophilic layer on NPs that triggers adsorptive-mediated transcytosis across the blood brain barrier (BBB) \[[@B92]\].

### 3.1.3. PEG-NP Covalent Conjugation {#sec3.1.3}

Covalent attachment of PEG to the functional groups of preformed NP surface is also possible which can minimize the displacement of adsorbed copolymers by blood opsonins. PEG derivatives can form covalent bond with thiols, glycosylated proteins, and amino acids allowing PEG to act as the spacer between the NP and the modifying ligand \[[@B28]\].

3.2. Physical Adsorption Methods {#sec3.2}
--------------------------------

In addition to covalent attachment methods, antibodies could also be attached to the NP surface following simple adsorption techniques, for instance, the development of cationic SMFv-polylys coated Paclitaxel loaded PLGA NPs. In this study, cationic polypeptide polylysine (polylys) was fused with SM5-1 scFv (SMFv) which was derived from SM5-1 mAb. The resulting positively charged fusion protein was tied with negatively charged Paclitaxel loaded PLGA NPs employing electrostatic interaction. The idea was to utilize the basic physicochemical properties of PLGA being negatively charged in neutral buffer where isoelectric point and electrostatic force strongly favor the adsorption of positively charged proteins on PLGA NP surface \[[@B93]\]. Following similar adsorption technique, transferrin and bovine serum albumin (BSA) were physically tagged with PLGA NPs where the protein ratio at 1/1 (w/w) was mixed with NPs (1 mg/ml concentration) with moderate shaking for 3 hours at room temperature \[[@B72]\]. However, the surface charge of PLGA NPs could be manipulated using different types of surfactants during NP preparation. Cetyltrimethylammonium bromide (CTAB) is an example of cationic surfactants which can be used in NP preparation to make positively charged NPs suitable for adsorbing plasmid DNA \[[@B94]\]. In another study to target human invasive ductal breast carcinoma, targeting ligands were physically linked to the NPs utilizing hydrophobic interaction between hydrophobic PLGA and hydrophobic part of the antibody molecule. In this study, slightly acidic phosphate buffered saline (PBS) of pH 5 was replaced with neutral buffer to facilitate the hydrophobic interaction \[[@B59]\]. Surface modification of hydrophobic NPs with hydrophilic PEG can also be performed by physical adsorption process \[[@B28]\]. Polysaccharides can form either monolayer or multiple layers around the NP core. A monolayer of cationic chitosan can be adsorbed onto PLGA chains of the NPs by electrostatic force \[[@B95]\]. Physical adsorption of more than one surface layer to PLGA NPs could be employed to target tumor cells efficiently. PLGA core could be physically coated with pluronic alone or a conjugate between heparin or chitosan to pluronic via urethane bond between the amine group of heparin or chitosan and hydroxyl group of pluronic \[[@B96]\].

4. Factors Controlling the Biological Response of Targeted NPs: Size, Surface Charge, and Storage Stability {#sec4}
===========================================================================================================

Some physiological parameters including renal and hepatic filtration determine the biodistribution and therapeutic efficacy of NPs depending on their particle size and surface compositions. However, a very few experiments have been investigated with only focus on size and surface charge of targeted PEG/PLGA NPs. Among those, one study revealed that the particle size 100--200 nm demonstrated enhanced accumulation in tumors compared to the size of NPs \< 100 and \>200 nm. Moreover, 50% clearance was observed for NP\'s size over 400 nm in spleen \[[@B97]\]. In general, studies suggested that the polymeric NPs of 100 nm size range could be optimum for EPR effect, higher plasma concentration, and accumulation in tumor tissues \[[@B98]\]. It is also concurrently understood that the surface charge of NP plays a key role in the therapeutic activity and efficacy. For example, a highly negative and positive surface charge-based NPs show higher RES uptake and blood plasma protein aggregation. However, neutral to ±10 mV surface charge-based NPs exhibit an enhanced circulation \[[@B98]--[@B104]\]. Although targeting approach is an emerging aspect of NP-based therapy, it may change the required physicochemical properties of NPs. Some researchers have demonstrated that ligand-based targeted NPs resulted in limited tumor penetration, intracellular drug decomposition, and enhanced blood clearance due to changes in NP\'s physicochemical properties \[[@B105], [@B98], [@B106]--[@B108]\]. However, some of the researchers found promising results when the polymeric NPs were decorated with suitable ligands without changing their physicochemical properties. [Table 2](#tab2){ref-type="table"} represents some recent studies for targeted PEG/PLGA NPs where the effects related to size and surface charge were comparatively discussed.

The results of these studies demonstrated the inevitability to control the size and surface charge of targeted NPs and could be a predictive guideline to formulate effective targeted therapeutic NPs before*in vivo* trials. However, a slight variation in size and surface charge of the NPs could make significant differences in both*in vitro* and*in vivo* studies.

The long-term storage of NPs is also an important parameter to scale up targeted nanoformulations. Irreversible aggregation may occur due to increased surface area of NPs when the formulations are stored for a longer duration. This can destabilize their physicochemical properties. The use of suitable cryoprotectant during lyophilization can be an approach to stabilize these PLGA NPs. Long-term storage of NPs with suitable cryoprotectant appeared to be stable without any polymer collapse or aggregation \[[@B109]\]. For example, Curcumin-loaded PLGA NPs were stable at room temperature and refrigerator even after 6 months of cryopreservation with 5% sucrose. It is anticipated that cryoprotectants provide a barrier on NP surface to prevent aggregation over the long-term storage \[[@B110]\]. It is important to have cryoprotected NPs as long-term storage leads to adsorption of moisture and reduction of *T*~*g*~ (glass transition temperature) below storage temperature, resulting in natural consequence of product collapse \[[@B111]\].

5. Biological Effects for Surface Functionalization of NPs {#sec5}
==========================================================

5.1. Surface Functionalization Using Antibodies {#sec5.1}
-----------------------------------------------

In order to target human invasive ductal breast carcinoma, antibody modified NPs following both covalent attachment and adsorption showed a comparative uptake in MCF-7 and MCF-10A neoT cells. These NPs were also found to be immune-specific since they were localized in antigen containing MCF-10A neoT cell lines rather than the antigen free CaCo-2 cells. Fluorescence microscopic study further confirmed that NPs with adsorbed mAbs showed higher binding to target cell than NPs with covalently linked mAbs. The hydrophilic surface of covalently attached NPs having defective antigen-binding domains could be responsible for hindering their uptake. In case of covalent binding, self-polymerization of the mAb could also take place and impede the binding ability of the mAb to its target leading to reduced biological activity \[[@B59]\]. In another study, anti-CD8 antibody was covalently attached to carboxylic ended PLGA through its amine group to prepare anti-CD8-PLGA NPs for targeting human CD8 antigen, a membrane protein which is an indicator of lymphoblastic leukemia cells. The internalization of anti-CD8-PLGA NPs in CD8 expressing cells occurred within one hour. But, the plain PLGA NP spreads randomly over the human embryonic kidney cell membrane surface for more than 24 hours \[[@B112]\].

When DTT is used for cleavage of disulfide bonds, its adsorption to the surface of NPs takes a longer period of time preventing the NP surface available for other conjugations. Besides, using TCEP shows the highest number of thiol groups to be introduced for covalent conjugation compared to DTT and EDAC \[[@B74]\]. Pseudomonas exotoxin A (PE) loaded PLGA NPs decorated with Fab fragments of a humanized SM5-1 mAb were more cytotoxic against hepatocellular carcinoma cell line than the exotoxin conjugated to the Fab fragment. Thus, they were more effective in inhibiting the tumor growth. PE-PLGA-SM5-1 NPs also showed lower immunogenicity than that of PE-SM5-1 conjugate. Additionally, the activity of the PE-SM5-1 conjugate was inhibited by anti-exotoxin neutralizing antibodies which resulted in low efficacy against the respective tumor cells. Therefore, the use of mutant immunotoxins could be replaced with exotoxin to be loaded into PLGA-SM5-1 NPs \[[@B79]\]. In addition, Kou et al. also prepared Paclitaxel loaded NPs and modified with SMFv linked to polylysine which showed specific binding affinity for SM5-1 binding protein expressed on the cancer cells followed by better cytotoxic effect than unmodified NPs. SMFv-polylysine acted as a ligand which retained the activity of parent antibody to recognize protein positive cells \[[@B93]\]. Interestingly, both SMFv-polylysine modified and unmodified NPs had similar cytotoxicity against cells having no SM5-1 binding protein expression. Moreover, biotinylated anti-mouse DEC-205 mAb attached to NP showed a proportional increase in both Interleukin-5 (IL-5) and IL-10 production with increasing antibody concentration to be used for conjugation \[[@B113]\]. Cytokine-based biotinylated antibody against CD4^+^ T lymphocytes linked to Avidin-Palmitate NPs promoted the potency of leukemia inhibitory factor cytokine 1000-fold over the soluble cytokine \[[@B114]\].

In another study, Chang et al. developed PLGA NPs decorated with BSA and transferrin following adsorption attachment procedure. Transferrin-PLGA NPs showed 20-fold higher endocytic competence for blood brain barrier than BSA-PLGA NPs. Filipin (caveolae-mediated endocytosis inhibitor) was used to show that transferrin-PLGA NPs were endocytosed via caveolae pathway. In contrast, uptake of BSA-PLGA NPs showed no reduction by filipin which was in support of its nonspecific endocytosis (adsorptive-mediated endocytosis) \[[@B72]\]. The PLGA polymers vary in their carboxylic acid group content. According to Scott et al., a higher density of carboxylic acid is associated with higher conjugation with antibody. Anti-siglec-7 polyclonal antibody was used to functionalize PLGA NPs of different contents of carboxylic acid group to target CD33 like siglec-7 receptor commonly expressed on most acute myeloid leukemia \[[@B115]\]. The density of polyclonal antibody on the NP surface was found variable with the amount of PLGA surface functional groups and their charge. Furthermore, the internalization of antibody was also influenced by the surface charge of the NPs. Fay et al. showed that the conjugation of AMG 655 death receptor 5 (DR5) specific antibodies (Conatumumab) to PLGA NPs was able to target DR5 receptors preferentially to induce subsequent apoptosis. This conjugation along with Camptothecin drug was able to show significant cytotoxic effect in colorectal cancer cells. Thus targeting the cancer cells along with chemotherapy was achieved \[[@B116]\].

5.2. Surface Functionalization Using Polysaccharide {#sec5.2}
---------------------------------------------------

A number of polysaccharide-decorated PLGA NPs have been summarized in [Table 3](#tab3){ref-type="table"}. Particularly, it was found that covalently linked chitosan-PLGA NP showed comparatively higher drug release than PLGA NPs due to availability of microchannels on the surface. Mitoxantrone release was increased due to availability of hydroxy group on the surface that endowed more hydrophilic environment for drug release compared to pure PLGA NPs \[[@B90]\]. Yuan et al. prepared chitosan-PLGA NPs that could successfully entrap negatively charged siRNA within the chitosan core. Cationic chitosan interacted with anionic PLGA to form chitosan loaded PLGA NP. Due to high zeta potential the NPs were able to bind to more siRNA which resulted in enhanced endocytosis and silencing efficacy of green fluorescence protein into the cells \[[@B117]\]. Thiolation of chitosan-PLGA NPs was reported with excellent mucoadhesion property compared to the nonthiolated NPs. Moreover, the cationic chitosan-thiobutylamidine NPs showed strong mucoadhesion or successful thiolation with the anionic sialic acid and sulfonic acid substrate of mucus layer which was confirmed by an escalation of zeta potential from −22.91 mv to 24.75 mv. Therefore, thiolated chitosan could be a suitable approach when the mucoadhesion property is required for the formulations \[[@B91]\]. The mucoadhesive property was further investigated by Vllasaliu et al., where the model chitosan NPs could change the distribution of tight junction protein, zonula occludens-1 (ZO-1) in Calu-3 (human bronchial carcinoma) cells. However, they were not able to cross the tight junction part due to their large size (around 339 nm). Although the bronchial membrane permeability was not improved, NP containing drug could remain at the mucosa for a longer time \[[@B118]\]. This nanoparticulate system was persuasive for the possibility of controlled drug release and its prevention from enzymatic degradation.

For brain-targeted delivery, trimethylated chitosan covalently attached with drug coenzyme Q~10~ could be employed to enhance the uptake by cerebral endothelium. Trimethylated chitosan-covered particles could easily transport coenzyme Q~10~ through BBB which was not attainable with plain PLGA NPs \[[@B92]\]. In another study, hydrophobically modified dextran could be grafted to PLA and used to form NPs. Silylation of dextran chain was reported to decrease in chain polarity which could be restored by ring opening polymerization in order to impart amphiphilic properties of polymer \[[@B119]\]. When the PLA chain in the graft was short, the NP size became higher due to desorption and induced partial aggregation. In contrast, higher density NPs of smaller size were obtained when dextran was coated on PLA \[[@B120]\]. Additionally, NPs with lower size could be obtained when hydrophobically modified dextran with cholesterol was used. PLA-dextran-cholesterol NPs could adsorb fluorescein isothiocyanate (FITC) labelled BSA to their surface. The accumulation of these modified NPs in RES was more than PVA/PLA NPs having a hydrophilic layer that protected PVA stabilized PLA NPs from blood protein interaction \[[@B121]\]. To increase the NP accumulation in glioma cells, transferrin ligand was coupled on the PLA-dextran-cholesterol NPs where indomethacin was loaded as drug. The ligand-NP conjugate was treated with sodium tetraborate to prevent the leakage of indomethacin. FITC labelled NPs showed a comparative internalization into the glioma cancer cells within 4 hours \[[@B122]\]. Surface functionalization of modified PLA NPs was also performed with two bioactive ligands CD71 mAb and EGFR polyclonal antibody. Hydrophobically cholesterol modified dextran was obtained by esterification of dextran polyaldehyde and then attached with the antibodies at the functional aldehyde end groups. In brief, the amine group of antibody was linked with the aldehyde group of dextran and cholesterol facilitated the anchoring of the polysaccharide antibody conjugate to PLA NPs. The accumulation of NPs with one ligand in glioma cells was less compared to that of NPs with both ligands. The relative radioactivity in brain was found significant for two antibodies containing NPs which confirmed the overexpression of both antibody specific receptors on glioma cells \[[@B123]\]. Another experimental design was adopted to encapsulate water-soluble drug (vincristine sulfate) into PLGA NPs using anionic dextran sulfate sodium. Drug encapsulation efficiency was higher while using polysaccharide in the formulation which could be attributed to the generation of electrostatic interactions between polysaccharide and drug \[[@B124]\]. According to Vautheir et al., BSA adsorption in the diffuse shell of dextran could not be prevented due to ability of BSA to change its own conformation. However, adsorption of larger proteins such as fibrinogen could be controlled by the density of the dextran chains \[[@B125]\].

Chung et al. compared the adsorption of heparin/chitosan-pluronic (PEO-PPO-PEO) conjugate onto the PEG-PLGA core with the control standard PEG-PLGA-Pluronic NPs. They showed that chitosan-PLGA NP and heparin-PLGA NP exhibited more accumulation (2.4-fold) in tumor cells compared to plain PLGA NPs. But the limitation was determined by the comparative localization of these NPs in liver which justified the lack of tumor specificity of NPs \[[@B96]\]. This nonspecificity could be overcome by modifying NPs with ligands such as folate and aptamer \[[@B70], [@B126]\]. Other ligands such as folic acid and PEG-folic acid could be also covalently attached to act as coating for alginate-chitosan multilayer. The presence of alginate in outer layer enhanced the hydrophilicity that could resist BSA to interact with NPs. This indicated a lower susceptibility of the NPs to protein binding. But, the electrostatic interaction could interplay between chitosan and BSA when chitosan was present in the outer layer. However, 10--20% higher cell uptake was found when the chitosan-alginate NPs were coated with PEG-folic acid. Thus, functionalization with folate ligand as well as layer-by-layer employment of polysaccharide was found effective in targeting cancer \[[@B127]\].

5.3. Surface Functionalization Using PEG {#sec5.3}
----------------------------------------

In general, long-circulating NPs of size below 500 nm are able to accumulate in the tumor tissue and release the therapeutic agent through EPR effect \[[@B128]\]. Active targeting helps to select the target cancer cells rather than just accumulating passively at the cancer site. Use of small ligand-PEG conjugate may provide better biodistribution and enhanced recognition and effective internalization into the cancer cells \[[@B129]\]. Although the use of "stealth" approach of PEG is widespread, however, limitation lies in low drug loading efficiency if the drug is conjugated to the PEG chains \[[@B31]\]. Also, surface adsorbed PEG can desorb leaving holes in the surface where the circulating opsonins can bind. Additionally, it is sometimes difficult to ensure the covalent binding of PEG chains to the surface \[[@B26]\]. [Table 4](#tab4){ref-type="table"} enlists the representative examples of PLGA NP formulations decorated with PEG.

Besides, loading of PEG into PLGA NPs was found more effective than its surface adsorption to the particles in terms of bypassing the RES and increasing half-life during circulation. This could be attributed to the fact that loading of PEG resulted in more hydrophilic surface of NPs compared to the adsorbed PEG. PEG-loaded particles showed less liver accumulation (13.9%) whereas adsorbed PEG particles accumulation reached about 21.8% after 3 hours of injection \[[@B130]\]. In addition, molecular weight of PEG could be a crucial factor as higher molecular weight PEG was found to be significant in both formulations. Covalently grafted copolymeric PLA-PEG NPs were found to show less plasma protein adsorption on their hydrophilic surface compared to the PLA-PEG-PLA multiblock copolymeric NPs. This effect could be correlated to the different percentages of exposed PEG on the NPs surface. In an*in vitro* uptake study, the diblock copolymers resulted in lower internalization compared to the multiblock copolymer. This was explained by the relatively hydrophilic and less negative surface charge of the diblock polymeric NPs compared to the multiblock polymeric NPs \[[@B131]\]. There are several PEGs based polymeric NPs in clinical trials; for example, PEG-PLGA/PLA NP loaded with Docetaxel is in phase II for treatment of prostate cancer. Another phase III trial is on poly-amino acid-PEG-cisplatin derived micellar NP to treat lymphomas and solid tumors \[[@B132]\].

The mechanism of action of PEG correlates to the water molecules that form hydrogen bond with the ether oxygen of PEG which in turn repels protein interactions \[[@B129]\]. The flexibility of PEG chains creates a hydrated cloud that excludes interaction with opsonins and complement proteins. The distance between the PEG chain and NPs creates a conformation change that could act as a shield to repel any particles \[[@B133]\]. It was found that pretreatment of Avidin-coated PLGA NPs with biotin-PEG reduces nonspecific protein adsorption (\<0.5 *μ*g/NP), whereas Avidin-coated NPs showed BSA adsorption of 1 *μ*g/NP. These PEG-modified NPs resulted in efficient release profiles of Doxorubicin with reduced cardiotoxicity. Taking serum creatine phosphokinase (CPK) as a measure of cardiotoxicity of Doxorubicin, it was found that the CPK was only 164 U/ml in PEGylated Doxorubicin loaded NPs compared to the free Doxorubicin (697 U/ml) treatment group \[[@B134]\].

The negative surface charge on NPs was found to activate the complement system proteins. It was reported that PEGylated PCL NPs recognition by MPS was assessed to be 45%, whereas non-PEGylated NPs showed about 90% MPS recognition just 5 minutes after injection \[[@B135]\]. NPs coated with PEG were also able to increase the bioavailability and pharmacokinetic profile of poorly water-soluble drug \[[@B136]\]. In another study, it was found that PEGylated NPs were able to accumulate in tumor graft within 7 hours; however PLGA NPs were not detectable in the respective tumor \[[@B137]\].

PEG present on NP\'s outmost layer can also be used to bind with ligands to target specific receptor which could be synergistic for NPs accumulation to the target site \[[@B138]\]. As a targeting ligand, folate is advantageous for its smaller size, simple conjugation chemistry, higher receptor affinity, lower immunogenicity, and limited expression in noncancerous tissues. PLGA-PEG-folate was found to have about 90% of entrapment efficiency of the anticancer drug (SN-38) while it was 77% for the non-PEGylated drug loaded NPs \[[@B139]\]. According to Farokhzad et al., nucleic acid ligand aptamer with amine (NH~2~) terminal could be covalently attached to PLA-PEG coblock having terminal carboxylic (COOH) group. It was reported that PEGylated-aptamer A10 NPs were competent to bind with the prostate cancer cell (77-fold higher than the control PEGylated NPs) \[[@B140]\]. Moreover, Docetaxel loaded PLGA-PEG-aptamer conjugate resulted in enhanced tumor size regression compared to empty NP, free Docetaxel, and Docetaxel loaded unmodified NPs in prostate cancer cell. A10 PSMA aptamer linked NPs were rapidly internalized in the tumor cell whereas lacking aptamer kept the particles onto the extracellular surrounding leading to rapid clearance \[[@B70]\]. Targeted delivery of cisplatin to prostate cancer cells was feasible via targeting PSMA using the aptamer attached to PLGA-PEG NPs.*In vitro* cytotoxicity assay showed that PSMA aptamer targeted cisplatin encapsulated NPs are 80 times more toxic than free cisplatin in the human prostate epithelial cells (LNCaP) \[[@B141]\]. When tested*in vivo*, this delivery system showed prolonged drug residence in blood with improved efficacy and tolerability over the free cisplatin \[[@B142]\]. In addition, biotinylated PEG-PLA block copolymers obtained via ring opening polymerization were successfully functionalized with transferrin that showed better internalization in C6 glioma cells compared to unmodified one. In a study, the intracellular uptake of transferrin modified NPs was 92.8% compared to about 68.3% uptake of plain PEG coated PLA NPs. The result indicated the advantage of ligand mediated active targeting over passive targeting \[[@B143]\]. Another study demonstrated that the hydrophilic nature of PEG was advantageous for binding of biotin which in turn resulted in significant binding of the fusion protein ligand linked to Streptavidin. This PLGA-PEG-ligand combination provided two advantages, one was the hindering of opsonins deposition and the other was the preferential uptake of ovalbumin loaded NPs by DEC-205 receptors \[[@B144]\].

6. Conclusion and Future Perspectives {#sec6}
=====================================

Research on structure-activity relationship of NPs is an ongoing trend for developing structurally sound delivery systems. Newer and advanced technologies to characterize drug delivery systems are continuously inspiring researchers to drive for targeted delivery of drug in the body. Application of targeted NPs promises to lead the advances in new classes of therapeutics. A multifunctional delivery system with various therapeutic cargo could be effective against cancer \[[@B145]\]. It is important to investigate these types of formulations in clinical trials. However, the duration of clinical trials, the cost of treatment, and less number of patients are the limiting factors. It is encouraging that the preliminary data has potential, but more research is required to understand the basic principles that are involved with those specific targeting approaches, the disease conditions, disease stages, and the mechanism of action of the drugs. More detailed knowledge is needed to interpret the routes of drug delivery to assist them in achieving the therapeutic level of drug at the site of action. In future, strategies to treat resistant tumors, brain tumors, and metastasis, multipurpose delivery device could be utilized based on the results and targets mentioned in the review.
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![Schematic representation of passive and active targeting approaches. The diagram includes different types of ligands that can be conjugated with NPs for active targeting. EPR, enhanced permeability and retention; NP, nanoparticle; PEG, polyethylene glycol.](JDD2017-9090325.001){#fig1}

![Schematic representation of ligand modified PLGA NPs by (a). Physical adsorption method and (b). Chemical conjugation methods, (1) carboxylic acid functionalized NPs form NHS-ester in presence of EDC and sulfo-NHS. NHS-ester reacts with primary amines to yield a stable amide bond, (2), (3), and (4). Thiol-maleimide reaction: activation of amine groups on NPs by SPDP and DTT followed by introduction of thiol groups that react with maleimide groups on the ligand, activation of carboxylic acid groups by EDC followed by introduction of thiol groups that react with maleimide groups on the ligand and maleimide coupling with activated thiol groups. (5) Noncovalent binding of biotin linked NP with ligand linked Streptavidin.](JDD2017-9090325.002){#fig2}

###### 

A brief overview and purposes of various actively targeted delivery systems using PLGA and PEG to their suitable targets.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target cells/diseases/animal models                                                         Targets                                                                            Targeted delivery system                                                                                                 Purpose of the study                                                                                                                                                                              Reference
  ------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------
  *(I) Transferrin ligand*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Leukemia (K562 cells)                                                                       Transferrin                                                                        Daunorubicin loaded PLGA-polylysine-PEG-transferrin                                                                      \(i\) To assess the antitumor efficacy of the delivery system with or without Daunorubicin/transferrin *in vitro* and *in vivo*                                                                   \[[@B146]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Brain capillary endothelial cells (BCEC) and astrocytes                                     Transferrin                                                                        PLGA NPs coated with bovine serum albumin/transferrin                                                                    \(i\) Evaluation of possible endocytosis mechanism for transferrin targeted brain drug delivery                                                                                                   \[[@B72]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Swiss albino mouse (female or male)                                                         Transferrin                                                                        Lamotrigine loaded PLGA NPs                                                                                              \(i\) Surface functionalization of NPs using transferrin and lactoferrin as ligand to deliver Lamotrigine to brain\                                                                               \[[@B147]\]
                                                                                                                                                                                                                                                                                                          (ii) The purpose was to improve the biodistribution and pharmacokinetic profile of drug as well as reduced accumulation in nontargeted organs (kidney, lung, liver, spleen, heart) of the mouse   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Pancreatic cancer cells                                                                     Transferrin                                                                        Bortezomib loaded PLGA NPs                                                                                               \(i\) To study the targeting efficiency and capacity of transferrin targeted NPs                                                                                                                  \[[@B148]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Breast cancer and glial cells                                                               Transferrin                                                                        Curcumin/5-fluorouracil loaded magnetic PLGA NPs                                                                         \(i\) To identify the mechanism of cell death by the dual drug transferrin targeted NPs\                                                                                                          \[[@B149]\]
                                                                                                                                                                                                                                                                                                          (ii) To identify the effect of magnetic hyperthermia to destroy cancer cells                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Brain glioma cells                                                                          Transferrin                                                                        Paclitaxel and Doxorubicin loaded magnetic silica PLGA NPs                                                               \(i\) To determine the transport efficiency through blood-brain barrier and target glioma cancer cells\                                                                                           \[[@B150]\]
                                                                                                                                                                                                                                                                                                          (ii) To investigate the therapeutic efficiency of targeted NPs in tumor bearing balb/c mice                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  *(II) Small peptides*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  *(1) Asparagine-glycine-arginine (NGR/RGD)*                                                                                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Human fibrosarcoma cell line (HT-1080) and human umbilical vein endothelial cells (HUVEC)   Aminopeptidase N (CD13)                                                            Docetaxel loaded PLGA-PEG diblock copolymer NPs                                                                          \(i\) Exploration of the targeting potential of the drug loaded PEG-PLGA NPs *in vitro* cell lines\                                                                                               \[[@B151]\]
                                                                                                                                                                                                                                                                                                          (ii) Evaluation of hematologic toxicity, antitumor efficacy, nephrotoxicity and hepatotoxicity in balb/c mice                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  *(2) cLABL peptide against ICAM-1*                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  A549 lung epithelial cells                                                                  Intercellular adhesion molecule-1 (ICAM-1)                                         Modified Pluronic® surfactant on PLGA NPs                                                                                \(i\) To find how NPs are targeted to lung epithelial cells via ICAM-1 to be internalized                                                                                                         \[[@B56]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  *(3) Cyclo-arginine-glycine-aspartate (c-RGD) and combinations*                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Choroidal neovascularization (CNV) induced rat                                              Integrin/Transferrin                                                               Antivascular endothelial growth factor intraceptor, Flt23K loaded PLGA-RGD/transferrin and/or PLGA-RGD-transferrin NPs   \(i\) To apply the targeted delivery of peptide modified PLGA NPs for the management of CNV, the cause of blindness due to macular degeneration                                                   \[[@B152]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Human pancreatic cancer and human glioblastoma                                              Integrin *α*~*v*~*β*~3~                                                            c-RGD-modified micelle-type PLGA-4-arm PEG                                                                               \(i\) To prove the use of multi-branched PLGA micelle as a diagnostic probe for pancreatic tumor detection                                                                                        \[[@B153]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  HUVEC cells                                                                                 Integrin *α*~*v*~*β*~3~                                                            Paclitaxel loaded PLGA-PEG NP or PEG-PCL (polycaprolactone) NP                                                           \(i\) To investigate the effect of RGD peptide to target tumor endothelium and to see the antitumor efficacy of Paclitaxel                                                                        \[[@B154]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  *(III) Folic acid and folic acid combinations with other ligands*                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Glioblastoma multiforme                                                                     Folate/lactoferritin                                                               Folic acid or lactoferritin modified Etoposide encapsulated PLGA NPs                                                     \(i\) Assessment of anti-tumor efficacy of Etoposide when encapsulated in the ligand-PLGA conjugate\                                                                                              \[[@B155]\]
                                                                                                                                                                                                                                                                                                          (ii) Identification of the expressions of folate and lactoferritin receptors in target cells                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Human epidermal carcinoma cells                                                             Folate                                                                             PLGA-folate and PLGA-RGD                                                                                                 \(i\) To confirm that surface modified NPs showed effective cellular uptake with no cytotoxicity                                                                                                  \[[@B156]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Human breast cancer cells (MCF-7)                                                           Folate                                                                             Vincristine sulphate loaded PLGA-PEG-folate NPs or PLGA-PEG-cell penetrating peptide R7                                  \(i\) To investigate the cell uptake capacity of the ligand-drug-PLGA conjugate and ligand-PLGA conjugate\                                                                                        \[[@B157]\]
                                                                                                                                                                                                                                                                                                          (ii) To evaluate the tumor targeting and antitumor efficacy in *in vivo* model                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Colorectal cancer                                                                           Folate                                                                             Folate modified Capecitabine loaded PLGA-PEG NPs and flate-PLGA-PEG NPs                                                  \(i\) To prepare the two blends of NPs to evaluate their control release properties                                                                                                               \[[@B158]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Cervical tumor cells and human ovarian cancer cells                                         Folate                                                                             Folate modified Quercetin loaded PLGA-PEG NPs                                                                            \(i\) To test the cytotoxicity profile, targeting effect and cell uptake properties of the folate expressing cancer cells\                                                                        \[[@B159]\]
                                                                                                                                                                                                                                                                                                          (ii) To demonstrate the active tumor targeting of folate bearing NPs                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  *(IV) Antibodies*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  SKBR-3 breast cancer cell                                                                   HER2                                                                               Anti-HER 2 trastuzumab antibody -modified Docetaxel-loaded PLGA                                                          \(i\) To point out the feasibility of ligand conjugation strategy and demonstrate its efficiency in cell uptake and cytotoxicity                                                                  \[[@B77]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  MCF-7 breast cancer cell                                                                    HER2                                                                               Anti-HER 2 trastuzumab antibody -modified human serum albumin NPs or gelatin NPs                                         \(i\) To observe the specific targeting of Herceptin conjugated NPs to Her2 overexpressed cells                                                                                                   \[[@B160]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Melanoma hepatocellular carcinoma and breast cancer cell                                    SM5-1 binding protein                                                              Paclitaxel loaded PLGA linked with SM5-1 single chain antibody (scFv) derived from SM5-1 monoclonal antibody             \(i\) To develop the targeted NP system and examine their specific binding, cross-reactivity and internalization\                                                                                 \[[@B93]\]
                                                                                                                                                                                                                                                                                                          (ii) To evaluate the *in vitro* cytotoxicity effect of Paclitaxel loaded targeted NPs                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Metastatic lesion of human prostatic adenocarcinoma                                         Androgen receptor (AR) and *β*-catenin                                             PSMA antibody conjugated PLGA-Curcumin NPs                                                                               \(i\) To generate an antibody conjugated targeted NP to target Ar/*β*-catenin in order to inhibit tumorigenesis                                                                                   \[[@B161]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  PSMA positive prostate cancer cell                                                          PSMA positive cell surface                                                         PLGA-PEG copolymer derived microbubble (MB) conjugated with urea based PSMA inhibitor molecular probe                    \(i\) To establish the MB-molecular probe conjugate and confirm their selective binding to PSMA positive cells                                                                                    \[[@B162]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  *(V) Aptamer*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  PSMA on the surface of prostate cancer cell                                                 PSMA                                                                               PLGA-PEG-Aptamer A10 triblock NPs                                                                                        \(i\) To determine the optimum surface density of aptamer on the NP surface for maximum uptake by prostate cancer cell both *in vivo* and *in vitro*                                              \[[@B163]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Carbohydrate and polysaccharide                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Dendritic cell                                                                              Mannose receptor                                                                   Mannan-decorated PLGA NPs                                                                                                \(i\) To incorporate mannose by covalent conjugation and adsorption method, compare the methods based on uptake of NPs by cells                                                                   \[[@B164]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Lung epithelium adenocarcinoma and human pulmonary microvascular endothelial cells          Hyaluronic acid (HA) receptor for HA NPs, for other systems it is not elucidated   Glycosaminoglycan such as heparin, HA, chondroitin sulfate and dermatan sulfate modified PLGA NPs                        \(i\) Evaluation of the toxicity profile of the NP systems\                                                                                                                                       \[[@B165]\]
                                                                                                                                                                                                                                                                                                          (ii) To validate the systems for lung cancer treatment                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  *(VI) Other ligands: nuclear localization signal (NLS) peptide*                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Breast cancer cell (MCF-7)                                                                  Cell nucleus                                                                       Doxorubicin loaded NLS-conjugated PLGA NPs                                                                               \(i\) To increase the concentration of Doxorubicin in cell nucleus via NLS targeted NPs\                                                                                                          \[[@B166]\]
                                                                                                                                                                                                                                                                                                          (ii) To study the antiproliferative activity of targeted NPs and nontargeted NPs                                                                                                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

An overview of different targeting ligand decorated PLGA NPs with their preparation methods, ligands used, payloads, size, and zeta potential.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NPs type    NP preparation method                     Targeting ligand                       Loaded Materials            Stabilizer       Cell line/animal model                     Average size\                      Zeta potential\                    Reference
                                                                                                                                                                                       (nm)                               (mV)                               
  ----------- ----------------------------------------- -------------------------------------- --------------------------- ---------------- ------------------------------------------ ---------------------------------- ---------------------------------- -------------
  PEG         Top-down strategic PRINT technique        Transferrin                            ---                         ---              HeLa, Ramos, H460, SK-OV-3, HepG2, LNCaP   (267 ± 49)--(292 ± 76)             (−35.6 ± 1.3)--(39.9 ± 1.7)        \[[@B167]\]

                                                                                                                                                                                                                                                             

  PEG-PCL     Dry-down method                           Alexa Fluor 647 (AF647)                ---                         ---              MDA-MB-468, MCF-7                          (26.4 ± 0.7)--(60.9 ± 0.7)         (−5.1)--(−7.3)                     \[[@B105]\]

                                                                                                                                                                                                                                                             

  PEG-PCL     Solvent evaporation                       Angiopep-2                             Paclitaxel                  Sodium Cholate   U87 MG, BCECs                              \<100                              (−3.08 ± 0.94)--(−3.28 ± 0.75)     \[[@B168]\]

                                                                                                                                                                                                                                                             

  PLGA        Nanoprecipitation                         g7 Peptide                             Loperamide, Rhodamine-123   Poloxamer 188    Tail vein in rats                          140--180                           −20                                \[[@B169]\]

                                                                                                                                                                                                                                                             

  PLGA        Modified solvent extraction/evaporation   Trastuzumab                            Paclitaxel                  PVA              Caco-2, SK-BR-3                            (293.8 ± 5.7)--(312.3 ± 8.2)       (−35.07 ± 1.68)--(−21.24 ± 2.11)   \[[@B170]\]

                                                                                                                                                                                                                                                             

  PLGA        Emulsion-solvent evaporation/extraction   Humanized anti-DC-SIGN (hD1)           FITC-TT peptide, DQ-BSA     PVA              Granulocytes, PBMCs                        202 ± 4, 239 ± 14                  (−28.6 ± 0.4), (−44.9 ± 1.8)       \[[@B171]\]

                                                                                                                                                                                                                                                             

  PLGA-PEG    Nanoprecipitation                         A10 PSMA aptamer                       Cisplatin                   ---              LNCaP, PC3                                 (131 ± 0.5)--(172 ± 3.4)           ---                                \[[@B141]\]

                                                                                                                                                                                                                                                             

  PLGA-PEG    Emulsion-solvent evaporation              Pep TGN                                Coumarin-6                  ---              bEnd.3                                     (104.17 ± 3.45)--(121.46 ± 0.76)   (−24.43 ± 0.22)--(−18.25 ± 0.88)   \[[@B128]\]

                                                                                                                                                                                                                                                             

  PLGA-PEG    Solvent-diffusion                         cRGD peptide                           Doxorubicin                 PEMA             MDA-MB-231, B16F10, MCF-7                  (366.6 ± 3.1)--(423.0 ± 16.6)      (−18.9 ± 2.4)--(−51.7 ± 3.1)       \[[@B172]\]

                                                                                                                                                                                                                                                             

  PLGA-PEG    Nanoprecipitation                         A10 2′-fluoropyrimidine RNA aptamers   Docetaxel                   ---              LNCaP                                      (153.3 ± 13.9)                     −42 ± 1                            \[[@B70]\]

                                                                                                                                                                                                                                                             

  PLGA--PEG   Emulsion-solvent diffusion                Folate binding protein                 Docetaxel                   PVA              SKOV3                                      (120 ± 5)--(216 ± 18)              (−6.27 ± 0.95)--(−12.2 ± 0.6)      \[[@B173]\]

                                                                                                                                                                                                                                                             

  PLGA-TPGS   Solvent extraction/evaporation            TPGS                                   Docetaxel                   TPGS             Caco-2, MCF-7                              (219.42 ± 5.24)--(253.51 ± 5.38)   (−21.87 ± 2.11)--(34.1 ± 4.28)     \[[@B174]\]

                                                                                                                                                                                                                                                             

  PLGA-TPGS   Solvent extraction/evaporation            Vitamin E TPGS-folate (TPGS-FOL)       Doxorubicin                 ---              MCF-7, C6 glioma                           (324 ± 5)--(359 ± 10)              ---                                \[[@B175]\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Some examples of polysaccharide decorated PLGA NPs with their preparation methods, payloads, antibody conjugation methods, size, and zeta potential.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Shell and Core                                               Cargo/label                               NP preparation method                       Conjugation technique                Average size (nm)             Zeta potential (mV)             Reference
  ------------------------------------------------------------ ----------------------------------------- ------------------------------------------- ------------------------------------ ----------------------------- ------------------------------- -------------
  Chitosan/PEG functionalized PLGA core                        Fluoresceinamine (FA)                     O/W emulsification solvent evaporation      Covalent conjugation                 329 (FA-chitosan-PLGA)\       19.7 (FA-chitosan-PLGA)\        \[[@B176]\]
                                                                                                                                                                                          324 (FA-PEG-PLGA)             −38.1 (FA-PEG-PLGA)             

                                                                                                                                                                                                                                                        

  Chitosan-PLGA engineered into mesenchymal stem cell          Paclitaxel, Curcumin                      O/W emulsification solvent evaporation      Chemical conjugation                 142                           9.22                            \[[@B177]\]

                                                                                                                                                                                                                                                        

  Heparin/chitosan-Pluronic on PEG-PLGA core                   Tetramethyl\                              Nanoprecipitation/solvent diffusion         Chemical conjugation                 144 (Hep-PLGA),\              −50 (Hep-PLGA), +38 (Ch-PLGA)   \[[@B96]\]
                                                               rhodamine isocyanate                                                                                                       134 (Ch-PLGA)                                                 

                                                                                                                                                                                                                                                        

  Chitosan coated on PLGA                                      siRNA                                     Double emulsification solvent evaporation   Surface adsorption                   263.73                        33.76                           \[[@B178]\]

                                                                                                                                                                                                                                                        

  Lecithin/chitosan on PLGA core                               Betamethasone-17-valerate (BSV)           Emulsion-diffusion evaporation              Ionic gelation                       280.9 (BSV-chitosan-PLGA)\    −5.62 (BSV-chitosan-PLGA)\      \[[@B179]\]
                                                                                                                                                                                          274 (BSV-chitosan-lecithin)   40.8 (BSV-chitosan-lecithin)    

                                                                                                                                                                                                                                                        

  6-Carboxyfluorescein-chitosan film on paclitaxel-PLGA core   siRNA                                     O/W emulsification solvent evaporation      Surface adsorption as film           204--543                      +16.9--31.2                     \[[@B117]\]

                                                                                                                                                                                                                                                        

  Dextran-cholesterol on PLA core                              99mTc                                     Co-dialysis                                 Covalent attachment                  119--201                      ---                             \[[@B123]\]

                                                                                                                                                                                                                                                        

  Dextran-cholesterol on PLA core                              Fluorescein isothiocyanate                O/W emulsification solvent evaporation      Covalent attachment                  105                           −11.9                           \[[@B121]\]

                                                                                                                                                                                                                                                        

  Dextran-cholesterol-aldehyde on PLA core                     Transferrin, fluorescein isothiocyanate   Co-dialysis method                          Covalent attachment                  100--150                      −2.8                            \[[@B122]\]

                                                                                                                                                                                                                                                        

  Alginate-chitosan on PLGA core                               Folic acid or Folic acid-PEG              Emulsion solvent evaporation                Covalent attachment                  ---                           ---                             \[[@B127]\]

                                                                                                                                                                                                                                                        

  Dextran-sulphate sodium and PLGA core                        Vincristine sulphate                      Nanoprecipitation                           Self-assembly                        128.3--133.0                  (−10.6)--(−13.8)                \[[@B124]\]

                                                                                                                                                                                                                                                        

  Trimethylated chitosan- on PLGA core                         Coenzyme Q~10~ and Coumarin-6             Nanoprecipitation                           Covalent attachment                  136.8--146.7                  17.7--21                        \[[@B92]\]

                                                                                                                                                                                                                                                        

  Chitosan-4-thiobutylamidine on PLGA core                     Curcumin                                  Emulsification solvent evaporation          Covalent attachment                  889.5                         24.75                           \[[@B91]\]

                                                                                                                                                                                                                                                        

  Chitosan on PLGA core                                        Mitoxantrone                              Emulsion solvent evaporation                Adsorption and covalent attachment   291 (adsorption)\             25.13 (adsorption),\            \[[@B90]\]
                                                                                                                                                                                          331 (covalent binding)        23.01 (covalent binding)        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Some examples of PEG-modified PLGA NPs with preparation methods, targeting ligands, size, zeta potential, and applications.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Polymer                                  Targeting ligand                               Conjugation method                        Average size\   Zeta potential\    Applications                                                                                                            Reference
                                                                                                                                    (nm)            (mV)                                                                                                                                       
  ---------------------------------------- ---------------------------------------------- ----------------------------------------- --------------- ------------------ ----------------------------------------------------------------------------------------------------------------------- -------------
  PEGylated PLGA                           A10 aptamer                                    Covalent conjugation                      188             N/A                Targeting human xenograft prostate cancer in mice                                                                       \[[@B180]\]

                                                                                                                                                                                                                                                                                               

  PLGA-PEG                                 ---                                            Covalent conjugation                      170             N/A                NPs encapsulating endostar slowed growth of tumor xenografts                                                            \[[@B181]\]

                                                                                                                                                                                                                                                                                               

  PEGylated PLGA                           cLABL                                          Covalent conjugation                      244             −23.3              Targeting the vascular endothelium with upregulated ICAM-1                                                              \[[@B182]\]

                                                                                                                                                                                                                                                                                               

  50/50 PLGA and Palmitate-Avidin          Biotinylated PEG, and horseradish peroxidase   Streptavidin-biotin noncovalent binding   170             −11.3              Diffusion of PEGylated particles cervical mucus was 3--10x higher than unmodified PLGA                                  \[[@B183]\]

                                                                                                                                                                                                                                                                                               

  PLGA-PEG                                 ---                                            Covalent conjugation                      148             1.84               Sustained release of 9-nitrocamptothecin                                                                                \[[@B184]\]

                                                                                                                                                                                                                                                                                               

  PLGA-PEG                                                                                Covalent conjugation                      65--100         N/A                Sustained release of adriamycin                                                                                         \[[@B185]\]

                                                                                                                                                                                                                                                                                               

  PLA-PEG                                                                                 Covalent conjugation                      952             Neutral            Reduced opsonization of NPs                                                                                             \[[@B186]\]

                                                                                                                                                                                                                                                                                               

  PLGA and PEG-distearyl\                                                                 Coemulsification                          20--40          −19.2              Higher Doxorubicin encapsulation efficiency, slower release rate, and rapid cellular uptake                             \[[@B187]\]
  Phosphoethanolamine (PEGPE)                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                               

  PLGA-mPEG                                                                               Covalent conjugation                      N/A             N/A                Reduction in protein adsorption on the surface films of PLGA-PEG (750 and 2000) compared to adsorption onto PLGA only   \[[@B188]\]

                                                                                                                                                                                                                                                                                               

  PLGA                                     PEG/poloxamer 407                              Coincorporation or surface adsorption     189--225        (−16.1)--(−20.3)   Increased blood circulation half-life of NPs                                                                            \[[@B130]\]

                                                                                                                                                                                                                                                                                               

  PLGA-PEG di-block (15% PEG with 5 kDa)                                                  Covalent conjugation                      114             −2.8               Higher cellular uptake of formulations containing 15% of PEG compared to 5% and 10% PEG-PLGA formulations               \[[@B189]\]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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